| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -59.4 | -62.2 |
| Net income | -59.5 | -62.3 |
| EPS (diluted, $ a share) | $-1.53 | $-1.77 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: IRON. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Disc Medicine, Inc.: key numbers
- Share price
- $76.59Close, Nov 16
- Market cap
- $3.49B
- Shares outstanding
- 45.54MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Disc Medicine, Inc.
All →Disc Medicine CMO William Jacob Savage Sells $1.36M of Stock
William Jacob Savage, CMO, sold 16,035 shares of Disc Medicine, Inc. at $85.09 a share, worth $1.36M in total on Nov 10, 2026. Shares held after the trade: 63,445 (-20.2%).
- Value
- $1.36M
- Shares
- 16,035
- Price
- $85.09
- Role
- CMO
- Holding change
- -20.2%
- Trade date
- Nov 10, 2026
Disc Medicine Financial Results
Disc Medicine reported Q3 2026 financial results and provided a corporate update, highlighting the successful Phase 3 APOLLO trial of bitopertin which met all primary and secondary endpoints. The company plans to resubmit its NDA for bitopertin by year-end 2026 and recently strengthened its balance sheet with a $486 million public offering in October, extending its cash runway into 2030.
“In our first pivotal trial readout as a company, APOLLO delivered strong and compelling evidence of the potential clinical benefit of bitopertin for patients with EPP. We look forward to engaging with regulators with the goal of bringing an important, innovative medicine to this community as efficiently as possible.”
John Quisel, J.D., Ph.D., President and Chief Executive Officer
“Alongside our anticipated end-of-Phase 2 FDA meeting for selcodebart in anemia of myelofibrosis in the fourth quarter and a strengthened balance sheet, we are well positioned to support the anticipated launch of bitopertin and advance two additional programs toward pivotal-stage development in 2027.”
John Quisel, J.D., Ph.D., President and Chief Executive Officer
Disc Medicine Capital Raise of $450M
Disc Medicine closed an underwritten public offering of 6,000,000 shares of common stock at a price of $75.00 per share, generating gross proceeds of $450 million. The company expects the net proceeds to extend its cash runway into 2030, supporting the clinical development and potential commercialization of its hematologic disease treatments, including bitopertin.
- Value
- $450M
Disc Medicine Director Kevin Bitterman Sells $3.34M of Stock
Kevin Bitterman, Director, sold 41,655 shares of Disc Medicine, Inc. at $79.95 to $80.23 a share (average $80.13) in 7 transactions, worth $3.34M in total between Oct 19, 2026 and Oct 21, 2026. Shares held after the trade: 12,991 (-2.0%).
- Value
- $3.34M
- Shares
- 41,655
- Average price
- $80.13
- Role
- Director
- Holding change
- -2.0%
- Trade date
- Oct 19, 2026 to Oct 21, 2026
Disc Medicine Clinical Trial Data
Disc Medicine announced positive topline results from its pivotal Phase 3 APOLLO trial of bitopertin in patients with erythropoietic protoporphyria (EPP). The trial met all primary and secondary endpoints, including a 41.4% reduction in whole-blood PPIX and a significant increase in pain-free light tolerance, with an NDA resubmission planned by the end of 2026.
- Term
- 6 months
“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”
John Quisel, J.D., Ph.D., President and Chief Executive Officer
“These results are compelling evidence of the clinical benefit of a mechanism aimed at reducing the production of PPIX, the fundamental cause of disease. It has been an incredible journey from establishing the original hypothesis of targeting heme synthesis in cellular models to seeing that biology translate into the clear and meaningful clinical effects from APOLLO.”
Will Savage, M.D., Ph.D., Chief Medical Officer